ondansetron has been researched along with palonosetron in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.61) | 18.2507 |
| 2000's | 16 (25.81) | 29.6817 |
| 2010's | 41 (66.13) | 24.3611 |
| 2020's | 4 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, NM; Brady, CA; Butler, AS; Choo, SH; Cioffi, CL; Cohen, ML; Dobritsa, S; Earley, WG; Fitzpatrick, K; Guo, C; Guzzo, PR; Hassler, C; Manning, DD; Masih, L; Naginskaya, J; Ryan, KN; Sikkander, MI; Usyatinsky, A; Wierschke, JD; Zhang, Z | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Clark, R; Eglen, RM; Hegde, SS; Johnson, LG; Lee, CH; Smith, WL; Whiting, RL | 1 |
| Aapro, M; Gralla, R; Labianca, R; Lichinitser, M; Macciocchi, A; Mezger, J; Peschel, C; Sleeboom, H; Tonini, G; Van Der Vegt, S | 1 |
| Grunberg, SM; Koeller, JM | 1 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| Board, R; Board, T | 1 |
| Aapro, MS; Bertoli, LF; Grunberg, SM; Lordick, F; Macciocchi, A; Manikhas, GM; Morrica, B; Olivares, G; Suarez, T; Tjulandin, SA; Yunus, F | 1 |
| Awab, A; Chaudhary, L; Hamadani, M; Tfayli, A | 1 |
| McNulty, R | 1 |
| Wilkes, G | 1 |
| Alt, J; Cantoreggi, S; Massuda, EB; Rojas, C; Rubenstein, E; Sebastiani, S; Slusher, B; Snyder, SH; Stathis, M; Thomas, AG; Zhang, J | 1 |
| Limebeer, CL; Litt, DE; Parker, LA | 1 |
| Barzal, J; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P | 1 |
| Billio, A; Clarke, MJ; Morello, E | 2 |
| Fowler, B; Klinger, E; Matta, L; McDonnell, A; Reddy, P; Voit, D; Yeh, YC | 1 |
| Cao, R; Dong, X; Huang, J; Liu, L | 1 |
| Atri, R; Bhutani, G; Dhankar, R; Gupta, MC; Kaushal, J; Kaushal, V; Verma, S | 1 |
| Bekele, BN; Blamble, DA; Borthakur, G; Cabanillas, M; Cortes, JE; Kantarjian, H; Mattiuzzi, GN; O'Brien, S; Xiao, L | 1 |
| Cho, EJ; Park, SK | 1 |
| Balu, S; Buchner, D; Feinberg, B; Gilmore, J; Haislip, S; Jackson, J; Jain, G | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Basu, A; Hembrom, BP; Naaz, A; Roy, A; Saha, D | 1 |
| Joo, J; Kim, JE; Lee, Y; Moon, YE | 1 |
| Apfel, CC; Jukar-Rao, S | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R | 1 |
| Ballinari, G; Barbour, SY; Cox, D; Morrow, GR; Schwartzberg, L; Thorn, MD | 1 |
| Ahmed, SR; Candiotti, KA; Cox, D; Gan, TJ | 1 |
| Brygger, L; Herrstedt, J | 1 |
| Hori, M; Horie, S; Horiguchi, K; Iino, S; Kondo, M; Maehara, T; Matsumoto, K; Murata, T; Ozaki, H; Shimada, S; Tsubone, H | 1 |
| Antony, J; Hemmelgarn, B; Hui, W; Hutton, B; Moher, D; Soobiah, C; Straus, SE; Struchkov, V; Tricco, AC | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Liu, G; Ma, R; Wu, A; Xiong, C; Xue, J | 1 |
| Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE | 1 |
| Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S | 1 |
| Du, Q; Xu, XL; Yu, B; Zhai, Q; Zhu, B | 1 |
| Arora, MK; Borle, A; Gouda, D; Goudra, B; Makkar, JK; Singh, PM; Sinha, A; Trikha, A | 1 |
| Barras, M; Butler, JP; Curley, C; Kennedy, GA; Nakagaki, M | 1 |
| Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM | 1 |
| Liu, Z; Ruan, L; Zhou, C; Zhu, Y | 1 |
| Basharova, E; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, A | 1 |
| Bao, Z; Liu, Q; Zhou, C; Zhu, Y | 1 |
| Deng, X; Kong, XR; Li, CC; Liang, X; Peng, L; Tan, J; Wang, S; Yang, C; Zhang, J; Zhao, Z | 1 |
| Jain, S; Kapoor, G; Koneru, S; Vishwakarma, G | 1 |
| Bashey, A; Holland, K; LaPorte, J; Leone, K; Morris, L; Solh, M; Solomon, S; Zhang, X | 1 |
| Barrucand, L; Carvalho Braga, EL; Cavalcanti, IL; Figueiredo, NV | 1 |
| Ahamed, S; Begum, M; Begum, R; Chowdhury, MG; Hossain, M; Hossain, MM; Shuvo, FR | 1 |
| Boddu, D; Chaudhary, NK; John, RR; Mahasampath, G; Mathew, LG; Nesadeepam, N | 1 |
| Badiuddin, F; di Cola, RS; Di Lorenzo, N; Giardiello, C; Ienca, R; Juneja, G; Lopez, G; Scozzarro, A | 1 |
| Chan, D; Chow, E; DeAngelis, C; McFarlane, T; McKenzie, E; Parsafar, S; Pasetka, M; Razvi, Y; Rico, V | 1 |
| Alves, RL; Campos, GO; de Castro Alves, LJS; de Jesus Martins, M; de Oliveira Junior, JCMF; de Oliveira, PRR; Jesus, GN; Lessa, CN; Módolo, NSP | 1 |
| Navari, RM | 1 |
| Burckart, G; Garimella, N; Griebel, D; Heinrichs, MT; Kim, I; Krudys, K; Kumar, S; Mehrotra, N; Momper, JD; Mulberg, AE; Mulugeta, Y; Nelson, R; Reaman, G; Sachs, H; Sinha, V; Yao, L; Zineh, I | 1 |
| Aizawa, F; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kanda, M; Murai, Y; Niimura, T; Okada, N; Yagi, K; Yoshida, A; Yoshioka, T; Zamami, Y | 1 |
| Chen, Y; Liang, J; Liu, S; Zhu, H | 1 |
17 review(s) available for ondansetron and palonosetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2003 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Dexamethasone; Female; Half-Life; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Protein Binding; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Neoplasms; Ondansetron; Palonosetron; Patient Satisfaction; Prognosis; Quality of Life; Quinolizines; Quinuclidines; Treatment Outcome; Tropisetron; Vomiting | 2005 |
The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting.
Topics: Adult; Algorithms; Antiemetics; Child; Dexamethasone; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Evidence-Based Medicine; Granisetron; Humans; Indoles; Isoquinolines; Nurse's Role; Nursing Assessment; Ondansetron; Operating Room Nursing; Palonosetron; Patient Selection; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Risk Assessment; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists | 2006 |
Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2010 |
WITHDRAWN: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Topics: Adult; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2013 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinolines; Long QT Syndrome; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists | 2015 |
Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis.
Topics: Antiemetics; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic; Time Factors | 2015 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting | 2016 |
Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.
Topics: Adult; Anesthesia, General; Antiemetics; Benzimidazoles; Granisetron; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Treatment Outcome | 2016 |
Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Topics: Antiemetics; Benzimidazoles; Cholecystectomy, Laparoscopic; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Metoclopramide; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic | 2016 |
5-HT3 receptor antagonists for the prevention of postoperative shivering: a meta-analysis.
Topics: Analgesics, Opioid; Granisetron; Humans; Indoles; Isoquinolines; Meperidine; Ondansetron; Palonosetron; Postoperative Complications; Postoperative Period; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Shivering; Surgical Procedures, Operative; Tropisetron | 2016 |
Effects of palonosetron and ondansetron on preventing nausea and vomiting after laparoscopic surgery.
Topics: Anesthesia, General; Antiemetics; Humans; Isoquinolines; Laparoscopy; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
Topics: Adult; Ambulatory Care Facilities; Antiemetics; Humans; Medical Oncology; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Outpatients; Palonosetron; Quality of Life; Radiotherapy; Serotonin 5-HT3 Receptor Agonists; Serotonin Antagonists; Vomiting | 2019 |
Evaluating the effect of anti-nausea drugs in IDO enzyme gene expression and preventing postoperative vomiting and nausea in patients undergoing general anesthesia: A Meta-analysis.
Topics: Anesthesia, General; Antiemetics; Gene Expression; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Randomized Controlled Trials as Topic | 2022 |
24 trial(s) available for ondansetron and palonosetron
| Article | Year |
|---|---|
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2003 |
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Double-Blind Method; Drug Administration Routes; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2011 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2010 |
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Isoquinolines; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2010 |
A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery.
Topics: Adult; Anesthesia; Antiemetics; Demography; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Incidence; Injections, Intravenous; Isoquinolines; Laparoscopy; Ondansetron; Palonosetron; Patient Satisfaction; Postoperative Nausea and Vomiting; Quinuclidines; Treatment Outcome | 2011 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Comparison of palanosetron, granisetron and ondansetron as anti-emetics for prevention of postoperative nausea and vomiting in patients undergoing middle ear surgery.
Topics: Adult; Antiemetics; Ear, Middle; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists | 2011 |
Anti-emetic effect of ondansetron and palonosetron in thyroidectomy: a prospective, randomized, double-blind study.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Double-Blind Method; Female; Humans; Isoquinolines; Middle Aged; Ondansetron; Pain Measurement; Pain, Postoperative; Palonosetron; Postoperative Care; Postoperative Nausea and Vomiting; Quinuclidines; Thyroidectomy; Treatment Outcome; Young Adult | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Pilot Projects; Prospective Studies; Quinuclidines; Vomiting | 2013 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Palonosetron versus ondansetron as rescue medication for postoperative nausea and vomiting: a randomized, multicenter, open-label study.
Topics: Adult; Antiemetics; Female; Humans; Isoquinolines; Male; Middle Aged; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines | 2014 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infant; Internationality; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Olanzapine; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Transplantation Conditioning; Treatment Outcome; Vomiting; Young Adult | 2017 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2017 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans; Infant; Infant, Newborn; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Vomiting | 2018 |
A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Vomiting | 2018 |
A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy.
Topics: Adult; Aged; Antiemetics; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Nausea; Ondansetron; Palonosetron; Quality of Life; Severity of Illness Index; Transplantation Conditioning; Transplantation, Autologous; Vomiting; Young Adult | 2019 |
Use of palonosetron and ondansetron in the prophylaxis of postoperative nausea and vomiting in women 60 years of age or older undergoing laparoscopic cholecystectomy: A randomised double-blind study.
Topics: Aged; Aged, 80 and over; Antiemetics; Cholecystectomy, Laparoscopic; Double-Blind Method; Female; Humans; Infusions, Intravenous; Middle Aged; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Pre-Exposure Prophylaxis | 2019 |
Efficacy of Palonosetron as Antiemetic Prophylaxis for Post Operative Patients.
Topics: Administration, Intravenous; Adult; Anesthesia, General; Antiemetics; Bangladesh; Cholecystectomy, Laparoscopic; Double-Blind Method; Granisetron; Humans; Middle Aged; Ondansetron; Palonosetron; Postoperative Complications; Postoperative Nausea and Vomiting; Prospective Studies; Serotonin 5-HT3 Receptor Antagonists | 2019 |
Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Vomiting | 2019 |
Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride.
Topics: Adult; Antiemetics; Female; Gastric Balloon; Humans; Male; Middle Aged; Obesity, Morbid; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Pyridines | 2019 |
Palonosetron versus ondansetron for prevention of nausea and vomiting after total abdominal hysterectomy under spinal anesthesia with intrathecal morphine: a double-blind, randomized controlled trial.
Topics: Adult; Anesthesia, Spinal; Antiemetics; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hysterectomy; Middle Aged; Morphine; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting | 2019 |
21 other study(ies) available for ondansetron and palonosetron
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
Topics: Animals; Cell Line; Disease Models, Animal; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Mice; Microsomes, Liver; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Agonists | 2011 |
Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
Topics: Administration, Oral; Animals; Bradycardia; Dogs; Dose-Response Relationship, Drug; Duodenum; Female; Ferrets; Granisetron; Hemodynamics; Injections, Intravenous; Injections, Subcutaneous; Isoquinolines; Male; Ondansetron; Palonosetron; Quinuclidines; Random Allocation; Rats; Serotonin; Serotonin Antagonists; Stereoisomerism; Vomiting | 1995 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron; Vomiting | 2005 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2005 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compounds; Palonosetron; Quinolizines; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Therapeutic Equivalency; Vomiting | 2007 |
Preventing emesis in lung cancer patients.
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Lung Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Vomiting | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Topics: Animals; Antiemetics; Binding Sites; Calcium; Cell Line; Granisetron; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Radioligand Assay; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Transfection | 2008 |
Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiemetics; Autoreceptors; Conditioning, Psychological; Dose-Response Relationship, Drug; Fluoxetine; Isoquinolines; Lithium Chloride; Male; Nausea; Ondansetron; Palonosetron; Quinuclidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2009 |
Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
Topics: Antineoplastic Agents; Carmustine; Emetics; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Nausea; Ondansetron; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2009 |
Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Ambulatory Care; Antiemetics; Antineoplastic Agents; Boston; Cisplatin; Drug Administration Schedule; Drug Substitution; Emergency Service, Hospital; Fallopian Tube Neoplasms; Female; Health Resources; Humans; Isoquinolines; Length of Stay; Middle Aged; Nausea; Ondansetron; Ovarian Neoplasms; Palonosetron; Patient Readmission; Premedication; Quinuclidines; Risk Assessment; Risk Factors; Serotonin Antagonists; Time Factors; Treatment Outcome; Vomiting | 2011 |
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Vomiting | 2012 |
Is palonosetron also effective for opioid-induced and post-discharge nausea and vomiting?
Topics: Antiemetics; Female; Humans; Isoquinolines; Ondansetron; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Thyroidectomy | 2012 |
Therapeutic action of 5-HT3 receptor antagonists targeting peritoneal macrophages in post-operative ileus.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Gastrointestinal Transit; Ileus; Indoles; Isoquinolines; Macrophages, Peritoneal; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neutrophils; Ondansetron; Palonosetron; Postoperative Complications; Quinuclidines; Receptors, Serotonin, 5-HT3; RNA, Messenger; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Tropisetron | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dexamethasone; Granisetron; Humans; Isoquinolines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Serotonin, 5-HT3; Vomiting | 2017 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Palonosetron; Retrospective Studies; Vomiting | 2020 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Granisetron; Humans; Infant; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Palonosetron; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting; Young Adult | 2020 |
Effects of 5-HT
Topics: Acute Kidney Injury; Aged; Animals; Benzimidazoles; Cisplatin; Disease Models, Animal; Female; Granisetron; Humans; Kidney; Male; Mice; Middle Aged; Nausea; Ondansetron; Organic Cation Transport Proteins; Palonosetron; Renal Elimination; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2021 |